Objective    To evaluate the effect of ursodeoxycholic acid (UDCA) in cholestatic liver disease at early stage in patients after allogeneic hematopoietic stem cell transplantation.     Methods    Twenty-six consecutive cases of cholestatic liver diseases after allogeneic hematopoietic stem cell transplantation were enrolled and randomly divided into 2 groups

the UDCA group (

n

=12) and the s-adenosyl methionine group (

n

=14). They received conventional pre-transplantation chemotherapy

and regular prevention and trea

tment for graft versus host disease. The patients of the UDCA group were taken UDCA tables at a dose of 14 mg·kg

-1

·d

-1

for 14 d

and those out of the other group were intravenously infused with s-adenosyl methionine at a dose of 1 g/d for 14 d. Clinical evaluation and laboratory testing for alanine aminotransferases (ALT)

aspartate aminotransferase (AST)

alkaline phosphatase (ALP)

gamma-glutamyl transpeptidase (GGT)

total bilirubin (TBIL) and direct bilirubin (DBIL) were assessed pre- and post- treatment. TBIL reduced by ≥75%

≥50% or ≤50% were regarded as marked effective

effective or ineffective.     Results    At the end of the treatment

the 7/12 of patients treated with UDCA had gotten marked effective

the 3/12 gotten effective

whereas 3/12 ineffective. In the s-adenosyl methionine group

ratio of the 3 outcomes were 3/14

3/14 and 8/14 respectively. Compared with pre-therapy

there was a significant decrease in the serum ALT

ALP and GGT levels after treatment in both group (

P

<

0.05). All patients completed their assigned treatment with no major adverse event.     Conclusion    UDCA  therapy appears to be effective

safe and tolerable in individuals with cholestatic liver diseases in allogeneic hematopoietic stem cell transplantation.